Hyderabad-based Nucelion Therapeutics, a subsidiary of biotechnology leader Bharat Biotech, has officially signed a major strategic agreement with precision oncology company VeGen Bio. Announced on Wednesday, this partnership focuses on manufacturing VL-2511, an advanced CAR-T cell therapy designed to treat multiple myeloma. The collaboration will leverage Nucelion's specialized manufacturing facilities in Hyderabad to scale up production and perform clinical technology transfers. This crucial partnership aims to significantly lower the high cost of cutting-edge cancer treatments and improve healthcare access for patients across India.

What Happened?

Under the new agreement, Nucelion Therapeutics will serve as the exclusive manufacturing partner for VeGen Bio's lead therapy candidate, known as VL-2511. VL-2511 is a Phase II clinical-stage dual-target CAR-T therapy specifically engineered to fight multiple myeloma, a rare form of blood cancer. Unlike conventional single-target treatments, this therapy targets two distinct markers, BCMA and CD19, on cancer cells. This dual-action mechanism helps prevent cancer cells from escaping detection by the immune system, showing strong clinical promise even in complex patient cases with extramedullary disease.

Nucelion will handle end-to-end technical responsibilities from its state-of-the-art facility located in Hyderabad. This single-site facility is designed to satisfy strict international and domestic regulatory guidelines set by India’s CDSCO, the US FDA, and Europe’s EMA. Nucelion's extensive operational role includes precision analytical testing, cell processing, vector transduction, controlled cryopreservation, and continuous quality checks. By managing all these complex steps under one roof, the company aims to streamline process development and optimize manufacturing yields.

Speaking on the strategic move, Dr. Raghu Malapaka, Chief Business Officer of Nucelion, emphasized that the collaboration builds essential domestic capacity to bring advanced gene therapies to more patients in need. Prashant Bhavar, Director at VeGen Bio, also noted that this joint effort establishes a strong domestic ecosystem capable of developing next-generation medical treatments right within India.

Key Highlights

Nucelion Therapeutics has entered into an exclusive manufacturing partnership with precision oncology company VeGen Bio.
The agreement focuses on producing VL-2511, an advanced CAR-T cell therapy targeting multiple myeloma.
VL-2511 is currently in Phase II clinical trials and uses a unique dual-target mechanism (BCMA and CD19) to combat blood cancer effectively.
Manufacturing will take place at Nucelion’s facility in Hyderabad, which meets CDSCO, US FDA, and EMA standards.
The primary goal of the alliance is to optimize manufacturing costs and make high-tech cancer treatments accessible to patients in India.
Nucelion will handle comprehensive technical operations, including cell processing, testing, cryopreservation, and quality control.

Why Does This Matter?

Advanced treatments like CAR-T cell therapy are often far too expensive for average families in developing countries like India. Currently, receiving cell and gene therapy usually requires sending patient samples overseas or importing specialized medicine at exorbitant prices. By establishing an end-to-end domestic manufacturing pipeline in Hyderabad, Nucelion and VeGen Bio are working to eliminate expensive supply chain costs. This local capability is expected to dramatically reduce the final treatment cost, giving hope to hundreds of cancer patients who otherwise could not afford such care.

Furthermore, this initiative represents a major step forward for India’s biotechnology and healthcare infrastructure. Successfully scaling up local production of complex biopharmaceutical products helps position India as a global hub for cell and gene therapy manufacturing. It ensures that local hospitals and medical centers can offer world-class treatment protocols without relying heavily on foreign suppliers. Ultimately, this partnership opens the door to safer, more affordable, and life-saving medical options for everyday citizens facing tough battles against cancer.